Free Trial
NASDAQ:ZLAB

Zai Lab Q1 2026 Earnings Results & Report

Zai Lab logo
$26.04 -0.38 (-1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$26.49 +0.45 (+1.74%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zai Lab reported Q1 2026 earnings on April 1, 2026. The company reported EPS of -$0.50, while revenue was $99.61 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Zai Lab EPS Results

Actual EPS
-$0.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Zai Lab Revenue Results

Actual Revenue
$99.61 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Zai Lab Q1 2026 Earnings FAQ

Zai Lab (NASDAQ:ZLAB) reported earnings of -$0.50 per share for Q1 2026. The report was announced on Wednesday, April 1, 2026.

Zai Lab reported revenue of $99.61 million for Q1 2026.

Zai Lab Earnings Headlines

I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Zai Lab Limited 2026 Q3 - Results - Earnings Call Presentation
See More Zai Lab Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zai Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zai Lab and other key companies, straight to your email.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases.

Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market.

Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements. These partnerships support the company’s efforts to develop treatments for patients in China and other markets.

View Zai Lab Profile